TY - JOUR
T1 - Ramucirumab for the treatment of gastroesophageal cancers
AU - Shimodaira, Yusuke
AU - Elimova, Elena
AU - Wadhwa, Roopma
AU - Shiozaki, Hironori
AU - Charalampakis, Nikolaos
AU - Planjery, Venkatram
AU - Blum, Mariela A.
AU - Esteralla, Jeannelyn S.
AU - Rogers, Jane E.
AU - Song, Shumei
AU - Ajani, Jaffer A.
N1 - Publisher Copyright:
© 2015 Informa UK, Ltd.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Introduction: In 2014, the US FDA-approved ramucirumab for use in the second-line setting of advanced or metastatic, gastric or gastroesophageal adenocarcinoma (GEAC) based on the result of Phase III clinical trials; REGARD and RAINBOW.Areas covered: We briefly review the mechanisms of angiogenesis, antiangiogenic therapy and current status of advanced GEAC treatment then highlight the challenges and future prospects of novel molecular-targeted agents.Expert opinion: Although both the REGARD and RAINBOW trials met their primary end points of significantly prolonged overall survival and progression-free survival, the magnitude of the difference is still relatively modest. Given that ramucirumab alone has a marginal effect, a combination of paclitaxel and ramucirumab is strongly preferred as a second-line therapy. To maximize the impact of ramucirumab in patients with GEAC, we can leverage the recent pharmacokinetics data of ramucirumab from the REGARD and RAINBOW trials. In addition, the quest for identifying biomarkers to select patients who are likely to benefit the most should continue. It is our firm belief that taxanes should no longer be added to the frontline regimens in most cases, given the success of the taxane/ramucirumab in the second-line setting.
AB - Introduction: In 2014, the US FDA-approved ramucirumab for use in the second-line setting of advanced or metastatic, gastric or gastroesophageal adenocarcinoma (GEAC) based on the result of Phase III clinical trials; REGARD and RAINBOW.Areas covered: We briefly review the mechanisms of angiogenesis, antiangiogenic therapy and current status of advanced GEAC treatment then highlight the challenges and future prospects of novel molecular-targeted agents.Expert opinion: Although both the REGARD and RAINBOW trials met their primary end points of significantly prolonged overall survival and progression-free survival, the magnitude of the difference is still relatively modest. Given that ramucirumab alone has a marginal effect, a combination of paclitaxel and ramucirumab is strongly preferred as a second-line therapy. To maximize the impact of ramucirumab in patients with GEAC, we can leverage the recent pharmacokinetics data of ramucirumab from the REGARD and RAINBOW trials. In addition, the quest for identifying biomarkers to select patients who are likely to benefit the most should continue. It is our firm belief that taxanes should no longer be added to the frontline regimens in most cases, given the success of the taxane/ramucirumab in the second-line setting.
KW - Angiogenesis
KW - Apatinib
KW - Gastric adenocarcinoma
KW - Gastroesophageal adenocarcinoma
KW - Ramucirumab
KW - Targeted therapy
KW - VEGFR2
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=84930175968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930175968&partnerID=8YFLogxK
U2 - 10.1517/21678707.2015.1040390
DO - 10.1517/21678707.2015.1040390
M3 - Review article
C2 - 27570714
AN - SCOPUS:84930175968
SN - 2167-8707
VL - 3
SP - 737
EP - 746
JO - Expert Opinion on Orphan Drugs
JF - Expert Opinion on Orphan Drugs
IS - 6
ER -